Business Wire Feed
Brighton Marine, Inc. Announces US Family Health Plan of Southern New England Provider Network Expansion Through Southcoast Health Network Agreement
BOSTON--(BUSINESS WIRE)--Brighton Marine, Inc. announced today a new agreement between US Family Health Plan (USFHP) of Southern New England and Southcoast Health Network that significantly expands access to primary and hospital care for eligible USFHP more...
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to more...
Align Technology to Speak at Upcoming Financial Conferences
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics more...
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion’s Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue more...
BioTalent Canada Breaks Barriers in Opening Applications for 2026 I.D.E.A.L. Scholarship™
OTTAWA, Ontario--(BUSINESS WIRE)--#ait--BioTalent Canada has opened applications for the third annual I.D.E.A.L. Scholarship which will close on June 8, 2026. Full details and application forms available on BioTalent Canada’s website. Breaking down financial barriers today more...
RecovryAI Announces FDA Breakthrough Device Designation for Patient-Facing Clinical AI
Emerging from stealth, RecovryAI introduces AI-powered, physician-prescribed Virtual Care Assistants for post-operative recoverySAN FRANCISCO--(BUSINESS WIRE)--RecovryAI today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Virtual Care Assistants more...
Resilience Care & InterSystems Partner to Streamline Oncology Care Pathways
PARIS--(BUSINESS WIRE)--InterSystems and Resilience Care announce a technology partnership aimed at improving the experience of patients and caregivers. By combining the expertise of Resilience Care, a major player in remote medical monitoring, with InterSystems IRIS® more...
Linnea Achieves CEP Certification for Cannabidiol Isolate
RIAZZINO, Switzerland--(BUSINESS WIRE)--#CEP--Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an active more...
Pacific Prime Takes the Top Individual Broker Award and the Top SME Broker at Cigna’s Annual Broker Awards in Dubai
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Pacific Prime, a leading international health insurance brokerage and employee benefits specialist, was awarded the Top Individual Broker award for six consecutive years and the Top SME Broker for the second more...
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule modulators Expanded collaboration into Ono’s other priority areas of interest, including neurology and immunology, following the ongoing more...
USANA Health Sciences to Participate in Upcoming Investor Conferences
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced that the Company will participate in the following upcoming conferences: Sidoti Small-Cap Virtual Conference Dates: March 18-19, 2026 Format: Fireside chat and one-on-one meetings more...
IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive more...
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, more...
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio
Radiobotics to join Medimaps Group, creating a global provider of AI-driven musculoskeletal (MSK) medical imaging software The transaction is expected to close following receipt of Danish foreign direct investment (FDI) approval and other customary closing more...
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard more...
Airgain and Nextivity Enter Strategic Partnership on Co-developing Next Generation Integrated 4G / 5G Solutions
SAN DIEGO--(BUSINESS WIRE)--$AIRG #5GCoverage--Airgain, Inc. (NASDAQ: AIRG), a leading provider of wireless connectivity solutions, and Nextivity, Inc., an industry leader in intelligent cellular coverage solutions, today announced they have entered into a Strategic Partnership Agreement more...
Genentech’s Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction - - FENhance 1 more...
PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies
— Proprietary In-Line Monitoring Technology Enables Seamless Scale-Up from Basic Research to Commercial Manufacturing —TOKYO--(BUSINESS WIRE)--PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage more...
Otsuka Medical Devices/Otsuka Pharmaceutical: Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and Commercially Available in Japan
TOKYO--(BUSINESS WIRE)--Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective more...
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage disease, regardless of tumor type, more...
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with RCC whose disease progressed on or after treatment with more...
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed more...
National Condom Month: Why Today’s Protection Is About Pleasure, Confidence and Connection, According to Sex & Relationship Expert, Dr. Deb Laino
PHILADELPHIA--(BUSINESS WIRE)--In recognition of National Condom Month, sex and relationship therapist Dr. Deb Laino is encouraging young adults to prioritize safer sex practices - not just for protection, but for the emotional and relational benefits more...
Novocure to Participate in 2026 Leerink Global Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)--$NVCR--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief Financial Officer, will take more...
RevolutionEHR Launches RevPay, Redefining How Optometry Practices Manage Cash Flow
SAN DIEGO--(BUSINESS WIRE)--#DigitalPayments--RevolutionEHR, the market-leading optometry-first operating platform, today announced the launch of RevPay, its fully embedded payments solution designed to help practices get paid effortlessly while recovering more of the revenue they earn. RevPay more...